GSK’s Anoro Ellipta Heads To FDA Panel With Higher Hopes For Higher Dose

The lead LAMA/LABA combination for COPD will be reviewed at the Sept. 10 session of the Pulmonary-Allergy Drugs Advisory Committee.

GlaxoSmithKline PLC’s Anoro Ellipta for chronic obstructive pulmonary disease medication goes before the Pulmonary-Allergy Drugs Advisory Committee Sept. 10 with mostly positive results that should give the company high hopes.

GSK is seeking approval of the combination of umeclidinium (UMEC), a long-acting muscarinic antagonist, and vilanterol (VI), a long-acting beta...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

US FDA Could Miss User Fee Spending Triggers With House FY 2026 Funding

 

FDA employees are concerned that while the budget authority total proposed for fiscal year 2026 meets the user fee appropriations' triggers, the FDA could have trouble meeting allocation triggers without cuts to non-review work.

PCMA, CVS, Cigna File Lawsuits Over ‘Dangerous’ Arkansas PBM Law

 
• By 

The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.